{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Granulocyte+colony-stimulating+factor+plus+placebo", "query": { "intervention": "Granulocyte colony-stimulating factor plus placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 38, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Granulocyte+colony-stimulating+factor+plus+placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T04:12:55.427Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03036488", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Epirubicin", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1174, "start_date": "2017-03-07", "completion_date": "2025-10-14", "has_results": false, "last_update_posted_date": "2025-10-29", "last_synced_at": "2026-10-01T04:12:55.427Z", "location_count": 47, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 38 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Monterey", "state": "California" }, { "city": "Whittier", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03036488" }, { "nct_id": "NCT02087176", "title": "A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Previously Treated Non Small Cell Lung Cancer" ], "interventions": [ { "name": "AZD1775", "type": "DRUG" }, { "name": "AZD1775 Placebo", "type": "DRUG" }, { "name": "Antimitotic Agent", "type": "DRUG" }, { "name": "pegfiligrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2014-03", "completion_date": "2015-05", "has_results": true, "last_update_posted_date": "2016-06-14", "last_synced_at": "2026-10-01T04:12:55.427Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Englewood", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02087176" }, { "nct_id": "NCT01311336", "title": "Evaluation of Loratadine for Prevention of Pegfilgrastim-Induced Pain", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pegfilgrastim-induced Back and Leg Pain" ], "interventions": [ { "name": "Loratadine", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Vermont", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2011-05", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-01T04:12:55.427Z", "location_count": 7, "location_summary": "Brewer, Maine • Scarborough, Maine • York Village, Maine + 4 more", "locations": [ { "city": "Brewer", "state": "Maine" }, { "city": "Scarborough", "state": "Maine" }, { "city": "York Village", "state": "Maine" }, { "city": "Glens Falls", "state": "New York" }, { "city": "Berlin Corners", "state": "Vermont" } ], "official_url": "https://clinicaltrials.gov/study/NCT01311336" }, { "nct_id": "NCT02465268", "title": "Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma Multiforme", "Glioblastoma", "Malignant Glioma", "Astrocytoma, Grade IV", "GBM" ], "interventions": [ { "name": "pp65-shLAMP DC with GM-CSF", "type": "BIOLOGICAL" }, { "name": "unpulsed PBMC and saline", "type": "BIOLOGICAL" }, { "name": "Td", "type": "DRUG" }, { "name": "Saline", "type": "DRUG" }, { "name": "pp65-flLAMP DC with GM-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 175, "start_date": "2016-08-09", "completion_date": "2023-11-30", "has_results": true, "last_update_posted_date": "2025-01-14", "last_synced_at": "2026-10-01T04:12:55.427Z", "location_count": 3, "location_summary": "Gainesville, Florida • Orlando, Florida • Durham, North Carolina", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02465268" }, { "nct_id": "NCT00201409", "title": "A Randomized Trial of GM-CSF in Patients With ALI/ARDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Respiratory Distress Syndrome, Adult" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 132, "start_date": "2004-07", "completion_date": "2009-06", "has_results": true, "last_update_posted_date": "2015-12-29", "last_synced_at": "2026-10-01T04:12:55.427Z", "location_count": 3, "location_summary": "Denver, Colorado • Atlanta, Georgia • Ann Arbor, Michigan", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00201409" }, { "nct_id": "NCT04351152", "title": "Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Coronavirus Disease 2019 (COVID-19) Pneumonia" ], "interventions": [ { "name": "Lenzilumab", "type": "BIOLOGICAL" }, { "name": "Standard of Care", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Humanigen, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 520, "start_date": "2020-05-05", "completion_date": "2021-03", "has_results": false, "last_update_posted_date": "2021-03-03", "last_synced_at": "2026-10-01T04:12:55.427Z", "location_count": 18, "location_summary": "Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04351152" }, { "nct_id": "NCT04211259", "title": "Loratadine for the Reduction of G-CSF Induced Bone Pain in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Plasma Cell Myeloma" ], "interventions": [ { "name": "Loratadine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2022-04-18", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-01T04:12:55.427Z", "location_count": 2, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04211259" }, { "nct_id": "NCT00662519", "title": "Neulasta in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 1 Diabetes" ], "interventions": [ { "name": "Neulasta (Pegylated)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Mixed Meal Tolerance Test (MMTT)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Blood test", "type": "OTHER" }, { "name": "DNA Test", "type": "OTHER" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "12 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "12 Years to 45 Years" }, "enrollment_count": 21, "start_date": "2008-04", "completion_date": "2014-03", "has_results": false, "last_update_posted_date": "2015-04-09", "last_synced_at": "2026-10-01T04:12:55.427Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00662519" }, { "nct_id": "NCT00046930", "title": "Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "daunorubicin hydrochloride", "type": "DRUG" }, { "name": "zosuquidar trihydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eastern Cooperative Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 449, "start_date": "2002-09-17", "completion_date": null, "has_results": true, "last_update_posted_date": "2023-07-05", "last_synced_at": "2026-10-01T04:12:55.427Z", "location_count": 91, "location_summary": "Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 67 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00046930" }, { "nct_id": "NCT01322490", "title": "A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostate Cancer Metastatic" ], "interventions": [ { "name": "PROSTVAC-V", "type": "BIOLOGICAL" }, { "name": "PROSTVAC-F", "type": "BIOLOGICAL" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "GM-CSF Placebo", "type": "OTHER" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Bavarian Nordic", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1297, "start_date": "2011-11-28", "completion_date": "2017-12-15", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-10-01T04:12:55.427Z", "location_count": 84, "location_summary": "Anchorage, Alaska • Scottsdale, Arizona • Berkeley, California + 68 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Marina del Rey", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01322490" } ] }